Genome wide copy number analysis and systematic mutation screening in 58 patients with hypogonadotropic hypogonadism

Capsule:
Molecular analyses of 58 patients with hypogonadotropic hypogonadism revealed the relatively minor contribution of known genetic defects, and identified submicroscopic genomic rearrangement and SOX3 and WDR11 mutations as rare etiologies.

Authors:
Yoko Izumi, M.D., Erina Suzuki, M.A., Susumu Kanzaki, M.D., Shuichi Yatsuga, M.D., Saori Kinjo, M.D., Maki Igarashi, Ph.D., Tetsuo Maruyama, M.D., Shinichiro Sano, M.D., Reiko Horikawa, M.D., Naoko Sato, M.D., Kazuhiko Nakabayashi, Ph.D., Kenichiro Hata, M.D., Akihiro Umezawa, M.D., Tsutomu Ogata, M.D., Yasunori Yoshimura, M.D., Maki Fukami, M.D.

Volume 102, Issue 4, Pages 1130-1136

Abstract:

Objective:
To clarify the molecular basis of hypogonadotropic hypogonadism (HH).

Design:
Genome-wide copy number analysis by array-based comparative genomic hybridization and systematic mutation screening of 29 known causative genes by next-generation sequencing, followed by in silico functional assessment and messenger RNA/DNA analyses of the mutants/variants.

Setting:
Research institute.

Patient(s):
Fifty-eight patients with isolated HH (IHH), combined pituitary hormone deficiency (CPHD), and syndromic HH.

Intervention(s):
None.

Main Outcome Measure(s):
Frequency and character of molecular abnormalities.

Result(s):
Pathogenic defects were identified in 14 patients with various types of HH, although oligogenicity was not evident in this patient group. As rare abnormalities, we identified a submicroscopic deletion involving FGFR1 and an SOX3 polyalanine deletion in patients with IHH, and a WDR11 splice site mutation in a patient with CPHD. No disease-associated polymorphism was detected in the 58 patients.

Conclusion(s):
The present study provides further evidence that mutations and deletions in the known causative genes play a relatively minor role in the etiology of HH and that submicroscopic rearrangements encompassing FGFR1 can lead to IHH as a sole recognizable clinical feature. Furthermore, the results indicate for the first time that polyalanine deletions in SOX3 and mutations in WDR11 constitute rare genetic causes of IHH and CPHD, respectively.

  • Shvetha Zarek

    This excellent study highlights that known gene mutations in HH comprise a small portion of genetic causes of HH, suggesting that the formative gene mutations are unknown. I was wondering if future directions include testing this same cohort for recently identified mutations as reported in the manuscript (FGF17, IL17RD,
    DUSP6, SPRY4, and FLRT3)? Thank you.

Translate »